Norwegian researchers develop nano-needles

New Drug Approvals

Pint-sized nail bed: a thin copper plate goes into the oven and out come needles that will force cells to accept the drug. Photo: NTNU

Links

http://www.manufacturingchemist.com/news/article_page/Norwegian_researchers_develop_nanoneedles/88641/cn48579?dm_i=8EU,1IFCK,9ETTTY,55585,1

View original post

Advertisements

Merck Provides Update on Phase III Clinical Program for Preladenant, the Company’s Investigational Parkinson’s Disease Medicine

New Drug Approvals

preladenant

Merck , known as MSD outside the United States and Canada, today provided an update on the clinical program for preladenant, Merck’s investigational adenosine A2A receptor antagonist for the treatment of Parkinson’s disease (PD). An initial review of data from three separate Phase III trials did not provide evidence of efficacy for preladenant compared with placebo…..read more at

Links

http://www.businesswire.com/news/home/20130523006358/en/Merck-Update-Phase-III-Clinical-Program-Preladenant

Preladenant (SCH 420814) was a drug that was developed by Schering-Plough which acted as a potent and selective antagonist at the adenosine A2A receptor. It was being researched as a potential treatment for Parkinson’s disease.Positive results were reported in Phase II clinical trials in humans, but it did not prove itself to be more effective than a placebo during Phase III trials, and so was discontinued in May 2013

View original post